Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow-to-Debt Ratio
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow-to-Debt Ratio of 0.19x as of September 2025, meaning its operating cash flow of ₩9.47 Billion could theoretically repay 0% of its total liabilities (₩50.75 Billion) in one year. Explore 023910 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daihan Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Also explore Daihan Pharmaceutical Co.Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year debt coverage analysis for Daihan Pharmaceutical Co.Ltd. For market capitalisation and broader financial context, see Daihan Pharmaceutical Co.Ltd (023910) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.74x | ₩35.64 Billion | ₩48.42 Billion | ▼ -12.3% |
| 2023 | 0.84x | ₩38.86 Billion | ₩46.28 Billion | ▲ +49.4% |
| 2022 | 0.56x | ₩29.00 Billion | ₩51.58 Billion | ▼ -3.5% |
| 2021 | 0.58x | ₩40.62 Billion | ₩69.73 Billion | ▲ +23.3% |
| 2020 | 0.47x | ₩33.63 Billion | ₩71.17 Billion | ▲ +7.3% |
| 2019 | 0.44x | ₩35.26 Billion | ₩80.08 Billion | ▼ -7.5% |
| 2018 | 0.48x | ₩44.94 Billion | ₩94.39 Billion | ▲ +59.5% |
| 2017 | 0.30x | ₩20.45 Billion | ₩68.52 Billion | ▼ -28.0% |
| 2016 | 0.41x | ₩27.92 Billion | ₩67.36 Billion | ▲ +43.0% |
| 2015 | 0.29x | ₩17.98 Billion | ₩61.99 Billion | ▲ +106.5% |
| 2014 | 0.14x | ₩9.48 Billion | ₩67.52 Billion | — |